FAIM
NPCE icon

Financial Advocates Investment Management’s Neuropace NPCE Stock Holding History

Financial Advocates Investment Management’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-23,000
Closed -$256K – 400
2025
Q2 		$256K Hold
23,000
– – 0.02% 536
2025
Q1 		$283K Hold
23,000
– – 0.02% 577
2024
Q4 		$257K Buy
23,000
+5,000
+28% +$43.5K 0.01% 639
2024
Q3 		$125K Buy
18,000
+3,000
+20% +$21.9K 0.01% 735
2024
Q2 		$113K Buy
15,000
+5,000
+50% +$50.4K 0.01% 702
2024
Q1 		$132K Hold
10,000
– – 0.01% 730
2023
Q4 		$103K Hold
10,000
– – 0.01% 700
2023
Q3 		$97.3K Hold
10,000
– – 0.01% 673
2023
Q2 		$44.9K Hold
10,000
– – ﹤0.01% 683
2023
Q1 		$46.4K Hold
10,000
– – ﹤0.01% 727
2022
Q4 		$14.9K Hold
10,000
– – ﹤0.01% 745
2022
Q3 		$38K Buy
+10,000
New +$48.2K ﹤0.01% 736

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
KLP
Kent Lake PR Anasco, Puerto Rico $198M AUM 5.21% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Financial Advocates Investment Management's NPCE Position: Q3 2025 in Review

Financial Advocates Investment Management sold out of Neuropace (NPCE) in Q3 2025, closing a stake of 23,000 shares — an estimated $256K sold.

Financial Advocates Investment Management first reported a position in NPCE in Q3 2022 and held it in 12 quarters. The position peaked at $283K in Q1 2025. 80 funds tracked by Wall St. Rank hold NPCE as of Q3 2025.

  • Financial Advocates Investment Management reported no remaining Neuropace position as of Q3 2025 after selling out during the quarter.
  • Financial Advocates Investment Management sold 23,000 Neuropace shares in Q3 2025, an estimated $256K.
  • Financial Advocates Investment Management first reported a position in Neuropace in Q3 2022 and held it in 12 quarters.
  • Financial Advocates Investment Management's Neuropace position peaked at $283K in Q1 2025.
  • 80 funds tracked by Wall St. Rank held Neuropace as of Q3 2025.

Based on Financial Advocates Investment Management's 13F filing for Q3 2025, filed 6 Nov 2025.